Difference between revisions of "Lifileuecel (Contego)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lifileucel NCI Drug Dictionary]: A preparation of autologous tumor infiltrat...") |
m |
||
| Line 6: | Line 6: | ||
*'''Brand name:''' Contego | *'''Brand name:''' Contego | ||
| + | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Tumor infiltrating lymphocytes]] | [[Category:Tumor infiltrating lymphocytes]] | ||
Revision as of 18:26, 24 March 2023
Mechanism of action
From the NCI Drug Dictionary: A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro.
Also known as
- Code name: LN-144
- Brand name: Contego